Madrigal Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
MDGL Nasdaq 2836 www.madrigalpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Madrigal Pharmaceuticals, Inc.

MDGL Secures Exclusive Global Right for MASH Treatment From PFE - Jan 12th, 2026 9:20 am
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility And Long Term Momentum - Jan 10th, 2026 11:09 am
Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe Downgrade - What's Changed - Jan 10th, 2026 1:12 am
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor - Jan 9th, 2026 6:00 am
Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal - Jan 9th, 2026 4:28 am
UTHR or MDGL: Which Is the Better Value Stock Right Now? - Jan 8th, 2026 9:40 am
Why Madrigal Pharmaceuticals Stock Slumped on Tuesday - Jan 6th, 2026 5:14 pm
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead - Jan 5th, 2026 3:05 pm
Madrigal Pharmaceuticals (MDGL): Reassessing Valuation After Strong 1‑Year Share Price Surge - Dec 19th, 2025 12:15 pm
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Dec 18th, 2025 2:05 pm
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - Dec 15th, 2025 2:05 pm
H.C. Wainwright Keeps Buy on Madrigal Pharmaceuticals (MDGL) on Strong Rezdiffra Uptake and F2/F3 MASH Patient Data - Dec 11th, 2025 5:44 am
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run - Dec 9th, 2025 3:25 pm
Madrigal Pharmaceuticals (MDGL): Rezdiffra’s Strong Launch Spurs Rethink of Blockbuster Potential and Current Valuation - Dec 5th, 2025 9:09 am
Madrigal (MDGL) Up 21.9% Since Last Earnings Report: Can It Continue? - Dec 4th, 2025 9:30 am
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones - Dec 3rd, 2025 9:30 am
Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug - Dec 1st, 2025 5:58 am
Is Madrigal Pharmaceuticals Still Attractively Priced After 42.6% Surge on R&D Progress? - Nov 28th, 2025 12:09 pm
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year - Nov 27th, 2025 11:23 am
As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones - Nov 19th, 2025 1:00 am